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ABSTRACT 
Objective: To analyze the immunoexpression of the COX-2, p53, and 
caspase-3 proteins in colorectal adenomas and non-neoplastic mucosa. 
Methods: 72 individuals were subjected to colonoscopy, which 
provided 50 samples of adenomas and 45 samples of non-neoplastic 
colorectal mucosa. The tissue samples were obtained via the tissue 
microarray technique and subjected to immunohistochemical analysis 
using primary anti-p53, anti-COX-2, and anti-caspase-3 antibodies. 
The positivity and intensity of the immunoreaction were classified. 
The analyzed variables were as follows: site of the adenomas in the 
colon, degree of dysplasia, size, and score of positivity and intensity 
of immunoexpression of the p-53, caspase-3, and COX-2 proteins. 
Results: The immunoexpression of mutated protein p53 was positive 
in 30 (60%) adenoma samples and negative in 20 (40%) adenoma 
samples. The immunoexpression of mutated protein p53 was negative 
in 39 (86.6%) samples and positive in 6 (13.3%) samples of the non-
neoplastic colorectal mucosa (p<0.0001). Significant differences 
were seen between both the largest size (p=0.006) and the highest 
degree of dysplasia (p<0.0001) of the adenomas and the intensity 
of immunoexpression of mutated protein p53. The positivity and 
intensity of immunoexpression of COX-2 (p=0.14) and caspase-3 
(p=0.23) showed no significant differences between the adenomas 
and the non-neoplastic colorectal mucosa. Conclusion: Mutated 
protein p53 was hyperexpressed in the adenomas compared with 
the non-neoplastic mucosa. Greater size and greater degree of 
dysplasia in the adenomas were associated with higher expression of 
mutated protein p53. The immunoexpression of COX-2 and caspase-3 
in the adenomas did not exhibit a correlation with the anatomical-
pathological features of the tumors and did not differ from the 
corresponding expression levels in the non-neoplastic mucosa. 
Keywords: Adenoma; Immunohistochemistry; Gene, p53; Caspase 
3; Cyclooxygenase 2; Intestine, large 
RESUMO
Objetivo: Analisar a imunoexpressão das proteínas COX-2, p53 e 
caspase-3 em adenomas colorretais e na mucosa não neoplásica. 
Métodos: Foram submetidos à colonoscopia 72 indivíduos que 
forneceram 50 amostras de adenomas e 45 de mucosa colorretal 
não neoplásica. Os tecidos foram obtidos pela técnica de arranjo em 
matriz (tissue microarray) e submetidos a estudo imunoistoquímico 
com anticorpos primários p53, COX-2 e caspase-3. A positividade e 
intensidade da imunorreação foram classificadas. Foram estudadas 
as seguintes variáveis: localização do adenoma no colo, grau de 
displasia, tamanho, e escores de positividade e intensidade da 
imunoexpressão das proteínas p-53, caspase-3 e COX-2. Resultados: 
Nos adenomas, a imunoexpressão da proteína p53 mutada foi 
positiva em 30 (60%) e negativa em 20 (40%) amostras. Na mucosa 
colorretal não neoplásica, a imunoexpressão da proteína p53 mutada 
foi negativa em 39 (86,6%) amostras e positiva em 6 (13,3%) 
(p<0,0001). Houve diferença significativa entre o maior tamanho 
(p=0,006) e o maior grau de displasia dos adenomas (p<0,0001) 
e a intensidade de imunoexpressão da proteína p53 mutada. A 
positividade e intensidade da imunoexpressão das proteínas COX-
2 (p=0,14) e caspase-3 (p=0,23), nos adenomas e na mucosa 
colorretal não neoplásica, não apresentaram diferença significante. 
Conclusão: A proteína p53 mutada é hiperexpressada nos adenomas 
em comparação com a mucosa não neoplásica. Nos adenomas, o 
maior tamanho e o maior grau de displasia foram associados à maior 
expressão da proteína p53 mutada. A imunoexpressão das proteínas 
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COX-2 e caspase nos adenomas não apresentou correlação com os 
aspectos anatomopatológicos e não foi diferente em termos de níveis 
de expressão correspondentes na mucosa não neoplásica.
Descritores: Adenoma; Imunoistoquímica; Genes p53; Caspase 3; 
Ciclo-oxigenase 2; Intestino grosso
INTRODUCTION
Genes upregulated in adenoma relative to normal tissue, 
which maintained increased expression in colorectal 
carcinoma and adenoma, would encode proteins 
suitable as putative targets for immunoprevention(1,2). 
The identification of early and easily detectable tumor 
markers, that might contribute to the treatment of 
colorectal carcinogenesis, as the biological mechanisms 
required for preinvasive adenoma to progress to 
carcinoma, is highly relevant subject(3,4). Despite constant 
improvement of staging methods for colorectal carcinoma, 
we also observed a high degree of unpredictability of 
results, demonstrating a greater need for knowledge of 
determinants of the evolution of neoplasia(5-8). 
Gene p53, which is considered a DNA replication 
inhibitor, participates in regulating apoptosis and 
blocking angiogenesis(2,9) and is considered a tumor 
suppressor gene. Mutations in this gene occur 
frequently in human cancer with important implications 
for cell apoptosis(10). Lung, breast, and colon cancers 
are frequently associated with mutations in p53 and 
hyperexpression of the encoded protein(9,10).
Caspase-3 plays an important role in intrinsic (or 
mitochondrial) and extrinsic (or cytoplasmic) activation 
pathways of apoptosis. The protein’s expression in the 
non-neoplastic mucosa and colorectal adenomas is a 
controversial issue in the literature(6,11,12).
Cyclooxygenase-2 (COX-2) participates in the response 
to inflammatory stimuli, growth factors, angiogenesis, 
hormones, mitogenesis, and carcinogenesis(9-16). COX-2 
inhibitors might reduce tumoral angiogenesis and promote 
apoptosis(17,18). Studies with animal and human models 
demonstrated that the use of COX-2 inhibitors can prevent 
or hinder the adenoma–carcinoma progression(17,19). 
The expression of COX-2 is significantly increased in 
tumor tissues(9,13). However, the mechanism behind the 
protective effect of COX-2 inhibitors against the normal 
mucosa–adenoma–carcinoma sequence has not been fully 
elucidated to date(17,19).
OBJECTIVE
To analyze the immunohistochemical expression of the 
p53, COX-2, and caspase-3 proteins in colon adenomas 
and in the non-neoplastic colorectal mucosa and to 
determine the possible association of this expression 




The study was approved by the Research Ethics 
Committee (number 0279/10) of Escola Paulista 
de Medicina da Universidade Federal de São Paulo 
(UNIFESP).
The present investigation was a retrospective study 
(from January 2005 to December 2006) that included 
biopsy samples of colorectal adenomas and non-
neoplastic mucosa resected during colonoscopies and 
removed from paraffin blocks. 
Sample characteristics
Included were adult patients of both genders with 
colorectal adenomas that were diagnosed upon 
anatomical-pathological examination. The exclusion 
criteria were patients with colorectal adenomas associated 
to colorectal carcinomas, inflammatory bowel diseases, 
colorectal polyposis syndrome, and age <18 years.
Ninety-five paraffin-block samples from 72 patients 
subjected to colonoscopy were obtained from THELAB 
Pathology Laboratory (Macaé, RJ, Brazil) and were 
analyzed. The samples were allocated to two groups: 
Group adenoma (GA), which comprised 40 patients 
with colorectal adenoma, and Group Control (GC), 
which comprised 32 patients without colorectal adenoma. 
Fifty adenoma samples were harvested from GA, and 
45 samples of non-neoplastic mucosa were harvested 
from GC.
GA included 21 (52.5%) males and 19 (47.8%) females, 
with a mean age of 57.8±13.1 years (28 to 83 years). GC 
included 17 (53.1%) males and 15 (46.9%) females with a 
mean age of 46.1±14.9 years (18 to 74 years).
Tissue samples and immunohistochemistry
Slides of the paraffin blocks were prepared and stained 
with hematoxylin-eosin (HE). The selected blocks were 
subjected to the tissue microarray (TMA) technique. 
The TMAs were prepared according to the technique 
described by Pires et al.(20,21). The TMA blocks and 
immunohistochemical analyses were performed at the 
Fonte Pathology Laboratory (Niterói, RJ, Brazil).
To ensure the representativeness of each area 
selected in the paraffin blocks for immunohistochemical 
analysis, two samples were collected from different 
sections of the same block.
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To prepare the histological slides, the TMA paraffin 
blocks were cut into 3-µm-thick sections and stained with 
HE. The immunohistochemical technique was performed 
according to protocols previously established by the 
laboratory. The following primary antibodies were used 
on the TMA slides: anti-protein p53 (clone SP5, code 
453R-14, Cell Marque Corp., Rocklin, California, USA), 
caspase-3 (polyclonal, code CP229A, Biocare Medical, 
Concord, California, USA), and COX-2 (clone SP21, code 
240R-14, Cell Marque Corp., Rocklin, California, USA). 
External cases (placenta, kidney, and liver) were added to 
each slide to identify the position of each case in the TMA. 
For the immunohistochemical reactions, 3-µm-thick 
histological sections were obtained and placed on 
histological slides previously treated with saline solution 
(Sigma Chemical Co., St. Louis, Missouri, USA), according 
to protocols previously established by the laboratory.
The intensity of the expression of p53, COX-2, 
and caspase-3 on the slides was semi-quantified as 
follows: negative or zero, mild or 1 (<10% stained 
cells), moderate or 2 (10 to 50% stained cells), and 
strong or 3 (>50% stained cells)(22). The microscopic 
analysis of the slides was performed under an optical 
microscope (Eclipse E200, Nikon, Japan), with a 400X 
final magnification. The HE-stained slides and the 
TMA slides were examined by two pathologists. The 
positive controls used for immunohistochemical analysis 
were tissues from human tonsils. As a negative 
control, the primary antibody was removed from the 
immunohistochemical reaction.
Data collection
The results were analyzed based on the following variables: 
size, site, histological type, and degree of dysplasia of the 
adenomas, as well as the intensity and distribution of the 
immunoexpression of p53, caspase-3, and COX-2 in the 
colorectal adenomas and non-neoplastic mucosa. 
Statistical analysis
Descriptive statistics were summarized as mean ± 
standard deviation (SD) or frequencies (percentages), as 
appropriate. The χ2 test was used for qualitative variables, 
e.g., frequencies and proportions. The statistical software 
used was Statistical Package for the Social Sciences 
(SPSS) for Windows, version 10.1 (SPSS Inc., USA). The 
level of significance was established as 5%. 
RESULTS
The mean size of the adenomas (GA) was 0.62±0.2mm 
(2 to 20mm). Of the 50 adenomas, 29 (58%) were 
tubular, 17 (34%) tubulovillous, and 4 (8%) villous. 
Dysplasia was mild in 25 (50%) tumors, moderate in 18 
(36%), and severe in 7 (14%). The most frequent site 
of the adenomas was the sigmoid colon, accounting 
for 17 (34%) tumors, followed by the transverse colon 
with 11 (22%), descending colon with 7 (14%), cecum 
with 7 (14%), ascending colon with 4 (8%), and rectum 
with 4 (8%).
Comparison of the immunoexpression of the p53, 
COX-2, and caspase-3 proteins between the colorectal 
adenomas and the non-neoplastic mucosa yielded a 
significant difference (p<0.0001) in the immunoexpression 
of p53 between GA and GC, whereas the expression 
of COX-2 (p=0.14) and caspase-3 (p=0.24) did not 
exhibit a significant difference (Table 1).
Significant differences were found (p<0.0001) 
between the immunoexpression of p53 in the various 
histological types of colorectal adenoma and the 
corresponding immunoexpression in the normal 
mucosa (Table 2). 
No significant association was found between the 
immunoexpression of COX-2 (p=0.08) and caspase-3 
(p=0.12) in t  he various histological types of colorectal 
adenomas and normal mucosa (Tables 3 and 4).
The association between the intensity of p53 
immunoexpression and the degree of dysplasia of the 
colorectal adenomas was significant (p=0.03). The 
relationship between the intensity of immunoexpression 
of COX-2 and caspase-3 and the degree of dysplasia of 
the colorectal adenomas was not significant (p=0.76 
and p=0.3, respectively). 
The association between the distribution of the mean 
size of the colorectal adenomas and the immunoexpression 
of p53, COX-2, and caspase-3 showed a significant 
difference (p=0.006).
Table 1. Immunoexpression intensity of the p53, COX-2, and caspase-3 proteins 











C A C A C A
0 39 (88.6) 20 (40) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2)
1 3 (6.8) 10 (20) 9 (20.0) 10 (20.4) 9 (20.0) 5 (10)
2 1 (2.3) 14 (28) 20 (44.4) 30 (61.2) 23 (51.1) 22 (44)
3 1 (2.3) 6 (12) 16 (35.6) 9 (18.4) 13 (28.9) 22 (44)
Total 44§ 50 45 49§ 45 50
p value <0.0001* 0.14 (ns) 0.23 (ns)
χ2 test. § One sample was lost; * significant. A: group with colorectal adenomas; C: group with non-neoplastic mucosa; 
ns: non-significant.
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DISCUSSION
Patients with adenomas exhibit a threefold increased 
risk of developing colorectal cancer, a risk that is even 
greater among patients who are older than 60 years 
and/or present with multiple colorectal adenomas(1). 
However, the relation between the histogenesis of 
colorectal cancer and genetic alterations, as well as 
the accumulation of biomarkers, is not sufficiently 
understood to date(2,3).
Most of the research on this subject has focused on 
the genes controlling apoptosis(4,5), which is a target of 
cancer treatment at several stages of the progression of 
tumors. Disorders in the regulation of the cell cycle and 
pathways of apoptosis occur frequently in the colorectal 
mucosa-adenoma-carcinoma sequence(5-8).
The present study assessed the expression of the 
p53, COX-2, and caspase-3 proteins in tubular, 
tubulovillous, and villous colorectal adenomas, as well as 
in the non-neoplastic mucosa of the colon, by means of 
immunohistochemical analysis using the TMA technique. 
Immunohistochemical expression of p53 occurs 
when it is inactive, and the protein accumulates inside 
the cell nuclei, which might be caused by mutations in 
the p53 gene or by protein inactivation mediated by other 
molecules, which by hindering the transformation of 
p53 from its monomeric to its tetrameric form, prevent 
p53 from binding to DNA and impede functionality of 
this protein(23).
The presence of a mutated p53 gene is frequent in 
the areas with greatest dysplasia of the adenomas(23). 
Kaklamanis et al.(23) assessed the expression of p53 
in 72 adenomas as to their size, histological type, 
and degree of dysplasia and demonstrated that only 
the latter exhibits a significant association with the 
expression of p53. The immunoexpression of p53 is 
absent in the non-neoplastic colorectal mucosa. In this 
study, the p53 protein was not expressed in 39 (88.63%) 
of the non-neoplastic mucosa samples. Regarding the 
size of the adenomas, greater expression of p53 was 
found in the largest tumors, confirming the results of 
Kaklamanis et al.(23).
Sheikh et al.(1) analyzed the expression of p53 in 42 
adenomas with high degrees of dysplasia, 15 of which 
also exhibited carcinomas, and found the expression of 
p53 in 27 (64.2%) cases. Among the adenomas with in 
situ carcinomas, 93% were p53-positive, whereas 48% of 
the colorectal adenomas without in situ carcinoma were 
p53-positive. Ieda et al.(24) studied the expression of p53 
in 139 colorectal adenomas, 57 colorectal adenomas 
with early carcinoma, and 12 samples of colorectal 
carcinoma. The results revealed a significantly higher 
level of p53 expression in the adenomas with a 
greater degree of dysplasia. Visca et al.(25) analyzed the 
immunoexpression of apoptosis-regulatory proteins 
(including p53) in one hundred adenoma samples, 
one hundred carcinoma samples, and one hundred 
samples of adjacent non-neoplastic mucosa. The p53 
protein was not expressed in any samples from the non-
neoplastic mucosa. The adenomas with a high degree 
of dysplasia exhibited higher expression levels of p53. 
Sheikh et al.(1) and Ieda et al.(24) showed that the p53 
protein expression increases with a higher degree of 
adenoma dysplasia. But these authors did not compare 
the results in tumors with non-neoplastic tissue. Visca 
Table 2. Number of adenomas and the corresponding percentage of the p53 
expression level in patients with non-neoplastic colorectal mucosa (control) and 






Control TA TVA VA
0 39 (88.6) 14 (48.3) 6 (35.3) 0 (0) 59
1 3 (6.8) 5 (17.2) 5 (29.4) 0 (0) 13
2 1 (2.3) 8 (27.6) 5 (29.4) 1 (25) 15
3 1 (2.3) 2 (6.9) 1 (5.9) 3 (75) 7
Total 44§ 29 17 4 94
χ2 test; p<0.0001. § One sample was lost. TA: tubular adenomas; TVA: tubulovillous adenomas; VA: villous adenomas; 
VA: villous adenoma.
Table 3. Number of samples and corresponding percentage of the COX-2 
expression level in patients with non-neoplastic colorectal mucosa (control) and 






Control TA TVA VA
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0
1 9 (20.0) 5 (17.2) 3 (18.7) 2 (50.0) 19
2 20 (44.4) 18 (62.1) 11 (68.8) 1 (25.0) 50
3 16 (35.6) 6 (20.7) 2 (12.5) 1 (25.0) 25
Total 45 29 16 4 94
χ2 test; p=0.29. COX-2: cyclooxygenase-2; TA: tubular adenomas; TVA: tubulovillous adenomas; VA: villous adenomas. 
Table 4. Number of samples and the corresponding percentage of the caspase-3 
expression level in patients with non-neoplastic colorectal mucosa (control) and 






Control TA TVA VA
0 0 (0.0) 1 (3.5) 0 (0.0) 0 (0.0) 1
1 9 (20.0) 3 (10.3) 1 (5.8) 1 (25.0) 14
2 23 (51.1) 14 (48.3) 8 (47.1) 0 (0.0) 45
3 13 (28.9) 11 (37.9) 8 (47.1) 3 (75.0) 35
Total 45 29 17 4 95
χ2 test; p = 0.44. TA: tubular adenomas; TVA: tubulovillous adenomas; VA: villous adenomas.
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et al.(25) compared the expression of p53 protein in 
adenomas, carcinomas, and non-neoplastic mucosa 
adjacent to colorectal carcinoma. These authors studied 
formalin-fixed, paraffin-embedded archival material 
from one hundred non-consecutive adenomas and one 
hundred adenocarcinomas, including adjacent-to-tumor 
non-neoplastic mucosa, and negative controls were 
obtained from colon resections for non-neoplastic 
disease. They suggested that the evaluation in concert 
of clinicopathological data and immunohistochemical 
markers on both normal and abnormal colon tissue 
provides an attractive model of tumor progression. 
In the study, we observed that p53 protein expression 
was higher in adenomas than in the colorectal mucosa 
of patients without adenomas or carcinomas, and the 
adenoma size correlated with increased expression of 
p53 protein.
Leonardos et al.(26) observed differences in the 
activity of caspase-3 in colorectal carcinomas compared 
with the non-neoplastic mucosa. The activity of caspase-3 
was significantly higher in the tumor tissue compared 
with the non-neoplastic mucosa. Guan et al.(12) found 
greater expression of caspase-3 in adenomas compared 
with the non-neoplastic colonic mucosa. However, 
Sena et al.(11) studied the expression of caspase-3 in 
microadenomas and the non-neoplastic colonic mucosa 
and determined low levels of active protein in the 
microadenomas. Inappropriate or reduced functioning 
of the apoptotic process might represent an important 
characteristic of tumor progression. In the present case 
series, the expression of caspase-3 did not significantly 
differ between the adenomas and the non-neoplastic 
mucosa or as a function of the anatomical-pathological 
features of the adenomas. 
Sato et al.(14) conducted a retrospective study assessing 
the expression of COX-2 in 95 adenomas and the adjacent 
colorectal mucosa and found greater expression of COX-2 
in the adenomas that exhibited higher degrees of dysplasia 
(with increased cell proliferation). McLean et al.(13) 
assessed the expression of COX-2 in adenomas and the 
colorectal mucosa, and did not find expression of COX-2 in 
the latter, whereas the expression was significantly higher 
in the adenomas compared with the normal mucosa. 
In that study, the COX-2 expression level was higher in 
adenomas >10mm and in adenomas with greater degrees 
of dysplasia. Sheehan et al.(9) assessed the expression of 
COX-2 in 123 adenomas and its relation with malignant 
transformation and found increased COX-2 expression 
levels that were proportional to the size, histological type, 
and degree of dysplasia of the adenomas. Wasilewicz et 
al.(19) evaluated the expression of COX-2 in colon polyps 
and found higher expression levels in the adenomas than 
in the non-adenomatous polyps. Greater expression of 
COX-2 was found in the highly dysplastic adenomas 
and in polyps that were larger than 6mm. However, 
Einspahr et al.(27) observed no significant relationship 
between the expression of COX-2 and the degree 
of dysplasia, the size, or the histological type upon 
analyzing 108 colorectal adenomas. Nevertheless, when 
the histological type and size (>7mm) of the adenomas 
were analyzed jointly, the expression levels of COX-2 
exhibited a significant increase. 
Sakuma et al.(28) analyzed the expression of COX-2 in 
21 patients with colorectal cancer. COX-2 was expressed 
in 8 (38.1%) samples, and there was no relation between 
the distribution and intensity of expression of this 
marker. Nakajima et al.(29) found increased expression 
levels of COX-2 in tissue samples of carcinoma and in 
the non-neoplastic colonic mucosa. In the present study, 
expression of COX-2 was found in the non-neoplastic 
mucosa and the colorectal adenomas, although without 
a significant difference. 
Han et al.(30) correlated the expression of COX-2 
with the tumor size in 50 colorectal adenomas and 
40 carcinomas and did not determine a significant 
relationship. In the present study, the association between 
the expression of COX-2 and the degree of dysplasia, size, 
and histological type of the adenomas was not significant. 
This lack of association is possibly observed because the 
size of most of the adenomas was <10mm, and there 
were only a few villous adenomas in the sample.
The strategy for treating colorectal carcinoma by 
activating apoptosis in tumor cells specifically expressing 
the receptors for proteins related to cell death 
induction is attractive. Promising results are expected 
from ongoing phase I/II clinical trials that prove the 
efficacy of this therapy with agonist antibodies and/or 
recombinant proteins, alone or in combination with 
chemotherapeutic drugs(31). However, fundamental 
questions need extensive studies before clinical application 
of this therapeutic modality can be considered safe. Their 
action must be selective and effective to reduce excessive 
systemic toxicity compared to normal cells. Moreover, 
better understanding of the signaling mechanisms triggered 
by genes that lead to the survival of cells resistant to 
apoptosis is needed(31).
CONCLUSION
Mutated protein p53 was hyperexpressed in the 
adenomas compared with the non-neoplastic mucosa. 
Increased adenoma size and degree of dysplasia were 
associated with higher expression of mutated p53. The 
immunoexpression of cyclooxigenase-2 and caspase-3 
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in the adenomas did not exhibit association with the 
pathological features of the tumor, and did not differ 
from the expression of these proteins in the non-
neoplastic colorectal mucosa. 
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